473 F.Supp.3d 1117
S.D. Cal.2020Background
- Kurin and Magnolia compete in blood-culture collection devices: Kurin Lock (diverts ~0.15 mL) and Magnolia’s Steripath (diverts ~1.5–2.0 mL). Steripath was marketed earlier and is FDA registered and listed.
- Magnolia relied on clinical evidence (notably the Rupp prospective controlled study and several other published and unpublished studies and customer data) reporting contamination reductions (87.6% in the controlled period; 92–93% in other comparisons).
- Kurin sued under the Lanham Act, California FAL and UCL alleging false and misleading advertising (claims about 92%/93% reductions, references to 30,000/100,000 cultures, statements that Steripath "eliminates" or "virtually eliminates" contamination, and statements about FDA status and product superiority).
- Motions: Kurin moved for partial summary judgment and on Magnolia’s counterclaims; Magnolia moved for summary judgment and to exclude Kurin’s experts. The parties submitted extensive briefing and exhibits.
- The court found most efficacy claims supported by clinical studies, excluded Kurin’s FDA-regulatory expert testimony (Shapiro), granted Magnolia summary judgment on Kurin’s claims, but granted Kurin partial summary judgment only that Magnolia’s claim that the 93% average was based on "multiple publications and peer-reviewed published studies" was literally false. Kurin’s requests for injunctive relief and summary judgment on counterclaims were denied.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Are Magnolia’s 92%/93% reduction claims literally false? | Kurin: percentages and characterization as an average are false or unsupported. | Magnolia: percentages are supported by Rupp and other studies, customer data, and advertising cites sources. | Court: Majority of the reduction claims are supported by studies; not literally false. Kurin failed to meet its burden except as to one specific representation (see next row). |
| Was the claim that the 93% average is based on "multiple publications and peer-reviewed published studies" literally false? | Kurin: 93% average was not derived solely from multiple peer-reviewed publications. | Magnolia: 93% average comes from a mix of published and unpublished clinical and customer data; it never said ‘‘only’’ published studies. | Court: Kurin established literal falsity as to advertisements that represented the 93% average as being based on "multiple publications and peer-reviewed published studies." Partial summary judgment for Kurin on that narrow point. |
| Are statements that Steripath "eliminates" or "virtually eliminates" contamination actionable falsehoods? | Kurin: claims overstate performance and are literally false. | Magnolia: statements, read in context, refer to very low contamination rates shown in studies; some language is puffery. | Court: "Eliminates" is aspirational/puffery and nonactionable; "virtually eliminates" is supported by cited study results (contamination reduced to around 0.2%) and is not literally false. |
| Were statements about Steripath being FDA registered/listed misleading about regulatory status or QSR/GMP compliance? | Kurin: statements create a false impression of FDA approval/clearance and that registration denotes QSR/GMP compliance. | Magnolia: Steripath is registered/listed and was inspected; Magnolia did not represent it had 510(k) clearance. | Court: Kurin failed to raise a genuine issue that customers were misled; expert Shapiro excluded as unreliable on purchaser perceptions; summary judgment for Magnolia on these claims. |
| Did Kurin prove causation/proximate cause and entitlement to damages or injunctive relief from the alleged false ads (e.g., 93% average)? | Kurin: Magnolia’s advertising harmed Kurin’s sales and market entry; expert Kennedy offers lost-profits and corrective-ad costs. | Magnolia: Kurin lacks evidence tying alleged deception directly to lost sales; Kennedy offers no causation analysis or consumer surveys. | Court: Kurin failed to prove proximate cause or irreparable injury; temporal correlation insufficient. Magnolia’s summary judgment on Kurin’s claims granted. |
| Is Kurin entitled to summary judgment on Magnolia’s counterclaims? | Kurin: its advertising is not literally false so counterclaims fail. | Magnolia: raised evidentiary disputes and identified advertising that could be false or misleading. | Court: Kurin did not carry its summary-judgment burden; motion denied. |
Key Cases Cited
- Southland Sod Farms v. Stover Seed Co., 108 F.3d 1134 (9th Cir. 1997) (Lanham Act literal falsity and consumer deception standards)
- Lexmark Int'l, Inc. v. Static Control Components, Inc., 572 U.S. 118 (U.S. 2014) (Lanham Act proximate-cause requirement for damages)
- Celotex Corp. v. Catrett, 477 U.S. 317 (U.S. 1986) (summary judgment burden-shifting principles)
- Nissan Fire & Marine Ins. Co. v. Fritz Companies, Inc., 210 F.3d 1099 (9th Cir. 2000) (summary judgment burdens when movant lacks trial burden)
- C.A.R. Transp. Brokerage Co. v. Darden Restaurants, Inc., 213 F.3d 474 (9th Cir. 2000) (moving party must produce evidence entitling it to directed verdict when it bears the trial burden)
- Anderson v. Liberty Lobby, Inc., 477 U.S. 242 (U.S. 1986) (summary judgment: inferences and burden to show genuine dispute)
- Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574 (U.S. 1986) (nonmoving party must produce specific facts showing genuine dispute)
- Newcal Indus., Inc. v. Ikon Office Solutions, 513 F.3d 1038 (9th Cir. 2008) (distinguishing puffery from verifiable false claims)
- eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (U.S. 2006) (four-factor test for permanent injunction)
- Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579 (U.S. 1993) (expert admissibility standard)
- Kumho Tire Co. v. Carmichael, 526 U.S. 137 (U.S. 1999) (Daubert principles apply to non-scientific expert testimony)
- Fortune Dynamic, Inc. v. Victoria's Secret Stores Brand Mgmt, 618 F.3d 1025 (9th Cir. 2010) (experience-based expert testimony may be admissible but must be reliable)
- TrafficSchool.com, Inc. v. Edriver, Inc., 653 F.3d 820 (9th Cir. 2011) (presumption of diversion in comparative-advertising cases)